drugset
drugset / Trial / NCT07141329

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

NCT07141329 ↗

Phase 2 Recruiting 100 enrolled Supernus Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.

Timeline

Start
2025-07-30
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SPN-817 Unknown 4 mg —

Indications

focal epilepsy